Drug intelligence / Profile preview

LAUR-004

Development stage: Preclinical
Lead developer: Lauren Sciences
Modality: Nanoparticles → Drug Delivery Systems, Peptides
Administration: Intravenous, Oral

Overview

LAUR-004 is a preclinical **V-Smart nanomedicine** candidate from Lauren Sciences for **chronic pain**. The product is described as a **nanoparticle-based peptide therapeutic** that packages an **enkephalin payload** for delivery across the central nervous system, with the company indicating targeting of the **entire CNS**. Its intended pharmacology is analgesia through delivery of enkephalin, an endogenous opioid peptide, leading to activation of opioid receptors after CNS distribution. Lauren Sciences has indicated preclinical efficacy with both **intravenous** and **oral** administration using its proprietary V-Smart platform.

Other names: enkephalin V-Smart nanomedicineV-Smart enkephalin nanomedicine

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on LAUR-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAUR-004.

Explore the full profile